Last reviewed · How we verify
Continuation phase fluoxetine
Fluoxetine is a selective serotonin reuptake inhibitor (SSRI) that increases serotonin availability in the brain by blocking its reuptake at the presynaptic neuron.
Fluoxetine is a selective serotonin reuptake inhibitor (SSRI) that increases serotonin availability in the brain by blocking its reuptake at the presynaptic neuron. Used for Major depressive disorder (continuation/maintenance phase), Obsessive-compulsive disorder, Panic disorder.
At a glance
| Generic name | Continuation phase fluoxetine |
|---|---|
| Also known as | Prozac |
| Sponsor | University of Texas Southwestern Medical Center |
| Drug class | Selective serotonin reuptake inhibitor (SSRI) |
| Target | Serotonin transporter (SERT) |
| Modality | Small molecule |
| Therapeutic area | Psychiatry / Mental Health |
| Phase | Phase 3 |
Mechanism of action
Fluoxetine selectively inhibits the reuptake of serotonin at the synaptic cleft, leading to increased serotonin concentration and enhanced neurotransmission. This mechanism is thought to improve mood and reduce symptoms of depression and anxiety disorders. The continuation phase refers to maintenance therapy following an acute treatment phase to prevent relapse.
Approved indications
- Major depressive disorder (continuation/maintenance phase)
- Obsessive-compulsive disorder
- Panic disorder
- Generalized anxiety disorder
Common side effects
- Nausea
- Headache
- Insomnia
- Sexual dysfunction
- Diarrhea
- Tremor
- Somnolence
Key clinical trials
- Comparative Effectiveness Research Trial for Antidepressant Incomplete and Non-responders With TRD (PHASE4)
- An Adaptive Treatment Strategy for Adolescent Depression-Continuation (PHASE1, PHASE2)
- Stepped Care for Depression and Musculoskeletal Pain (PHASE4)
- Continuation Electroconvulsive Therapy (C-ECT) for Relapse Prevention in Major Depression (PHASE4)
- Cognitive Therapy for Recurrent Depression (PHASE3)
- Determining Optimal Continuation Treatment Duration for Depressed Children and Adolescents (NA)
- Cognitive Behavioral Therapy for Depression Relapse Prevention in Children and Adolescents (NA)
- Prozac Treatment of Major Depression: Discontinuation Study (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: